Important Information for Investors of Capricor Therapeutics
NEW YORK, September 2, 2025, a key date for investors tracking the developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who acquired securities of the firm between October 9, 2024, and July 10, 2025, should be aware of the actions they can take to potentially recover losses.
Why This Matters
The Rosen Law Firm, recognized for its extensive experience in protecting investor rights, is reminding affected investors of critical deadlines. The lead plaintiff deadline is set for September 15, 2025. Those who sustained losses exceeding $100,000 during the specified Class Period should seek counsel to address their concerns effectively.
What Investors Need to Know
Investors are entitled to compensation for their losses based on a contingency fee arrangement. This means individuals can pursue their claims against the firm without upfront costs. This approach empowers investors to focus on maximizing their recovery without the stress of initial financial outlay.
Steps to Join the Class Action
Joining the class action litigation is straightforward. Interested parties are encouraged to reach out to experienced legal counsel. For specific information and guidance, investors can contact Phillip Kim, Esq. at the Rosen Law Firm. It's crucial for individuals to ensure they file their claims no later than the stated deadline to be eligible for benefits.
Why Choose Rosen Law Firm?
Rosen Law Firm has built a strong reputation, achieving significant settlements for investors over the years. They emphasize the importance of selecting skilled counsel, especially since some firms might not have the necessary experience in litigating securities class actions. Capricor's case is highlighted as a noteworthy example, given the substantial safety and efficacy claims made regarding their drug candidate intended for treating Duchenne muscular dystrophy (DMD).
The Case Background
The lawsuit asserts that throughout the Class Period, Capricor's management provided misleading information about its lead therapy, deramiocel. Confounding evidence contradicted positive statements made by the defendants, including the drug's clinical trial data. As a result, investors purchased Capricor securities at inflated prices. When the actual details about the therapy and its trial results became public, it resulted in a significant decline in stock value, contributing to the losses faced by shareholders.
Investor Participation and Representation
No class has been certified at this point, meaning that investors should take proactive steps to retain counsel of their choosing. A lead plaintiff who represents the class can help guide the case forward; however, it's important to note that participating in the litigation process is not mandatory to later claim damages.
Contacting Rosen Law Firm
For any inquiries, interested parties are encouraged to contact the Rosen Law Firm directly for guidance. Their experienced team is well-equipped to help navigate the complexities of class action suits.
Follow them for updates on various platforms. Stay informed about ongoing news related to Capricor Therapeutics and similar litigation matters that may impact your investments.
Frequently Asked Questions
What should I do if I invested in Capricor during the Class Period?
If you invested during the specified timeframe, consider contacting legal experts to assess your potential for recovery.
How can I join the class action?
To join, investors need to reach out to legal counsel who can provide the necessary steps and ensure timely filing.
What is the deadline for filing a claim?
The lead plaintiff deadline is September 15, 2025. It's essential to act promptly to secure your position.
Why is it crucial to have experienced legal counsel?
Experienced counsel, such as Rosen Law Firm, has a proven track record in handling securities cases, which can greatly influence the outcome.
Can I still participate if I don’t want to be a lead plaintiff?
Yes, you can still benefit from the proceedings as an absent class member without taking on the lead plaintiff role.
